Maria Diab

Maria Diab practices at Henry Ford Hospital in Detroit, Michigan, part of Henry Ford Health.

Maria Diab's NPI, 1003259045, was assigned on April 9, 2013. Maria Diab holds Michigan license 4301103541.

Maria Diab's primary practice is Henry Ford Hospital, at 2799 W Grand Blvd, Detroit, MI 48202 in Wayne County. The practice phone is (313) 916-2600.

Maria Diab's primary practice is Henry Ford Hospital in Detroit, Michigan, part of Henry Ford Health. Maria Diab is also affiliated with DMC Detroit Receiving Hospital. The medical group on file is Henry Ford Health. Dmand AI also links Maria Diab to 2 more hospitals and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Maria Diab practices, 4 sites in all. Vendor and product names are available with a free account.

Internal medicine is Maria Diab's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Maria Diab is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Maria Diab's licenses on file in 2 states: Michigan and Georgia.

CMS data shows 395 Medicare services from Maria Diab across 5 procedure codes in 2024, for 109 Medicare patients. Medicare paid $26,334 for them.

CMS counts 109 Medicare patients who saw Maria Diab in 2024. The largest group is 65 to 74, with 56 patients. 75% of them have high blood pressure, and 73% have high cholesterol. 18% are also on Medicaid. Their average risk score is 2.45, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Maria Diab's median patient age at 69, with 62% women.

In 2024, Maria Diab wrote 732 Medicare Part D claims for 143 patients. 91% of them were for generic drugs. CMS names the drug for 513 of them, across 13 drugs with 11 or more claims each, at $38,450 in total drug cost. In 2023, CMS named 335 claims across 12 drugs.

Maria Diab accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Maria Diab as offering telehealth.

Dmand AI links 19 papers to Maria Diab, published from 2015 to 2025. 2025 was the busiest year, with 3. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Adenocarcinoma and Biomarkers, Tumor. Maria Diab has published most often in Cancer Metastasis Rev. Maria Diab's most frequent co-authors are Olatunji B. Alese, MD, Mehmet Akce, MD and Bassel Fouad El-Rayes, MD.

Dmand AI links Maria Diab to 9 clinical trials, 3 of them phase 1 studies. 6 are still active or recruiting. Conditions studied include Colorectal Neoplasms, Rectal Diseases and Carcinoma, Renal Cell. Emory University sponsors the most, 2.

CMS Open Payments shows 29 general payments to Maria Diab from 17 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 49% of the total. AstraZeneca Pharmaceuticals LP paid the most, $1,889.